Cambridge Laboratories in fact payment for services the provider of laboratory testing. She spends less than 0.5% of revenue on research and development and has relatively few patents for biotechnology companies. He now has the opportunity to invest $ 5 million to a joint venture with an Australian company proteomics, which works on drug discovery (royalty) model. The founder of the company believes that its technology could eventually lead to the discovery of new drugs that will generate substantial royalties. Although proteomics company has excellent technology, some of the thought leaders in the area for its employees, and partnerships with some impressive company, its technology is not yet proven. Cambridge Labs is also concerned that existing relationships with major pharmaceutical companies could be in jeopardy if he starts to take intellectual property position in proteomics. In addition, the Australian company consists mainly of doctors in the field of molecular biology, while Cambridge Labs dominated business leaders, the focus creates a strong financial returns for our shareholders. Cultural differences between the Australian research-oriented laboratory and publicly traded American company outsourcing has become apparent during the negotiation phase of a joint proposal by the company. "Hide
by Henry W. Lane, David Wesley, Dennis Shaughnessy Source: Richard Ivey School of Business Foundation 24 pages. Publication Date: March 23, 2004. Prod. #: 904M13-PDF-ENG
Related Case Solutions & Analyses:
London Public Library
Introductory Note on Financial Statements
College Couriers Inc.
Middlesex Mushrooms Limited (B)
Professor Proposes
Lucent in India
Microsoft Security Response Center (A)
Napster: Catalyst for a New Industry or Just Another Dot.Com
British Columbias Pharmanet Project
Beijing Mirror Corp.
